Article Sidebar
Views PDF: 306
MEDICATION USE IN TREATMENT OF TYPE 2 DIABETES MELLITUS IN PATIENTS WITH KIDNEY FAILURE AT CAN THO GENERAL HOSPITAL IN 2020-2021
Main Article Content
Abstract
Background: Treatment of diabetes mellitus in the presence of kidney injury is very important to maintain or prolong the life of patients who have applied renal replacement therapy. Objectives: Determining the proportion of medicines and glycemic control for type 2 diabetes mellitus in patients with kidney failure at Can Tho General Hospital in 2020-2021. Materials and methods: A cross-sectional descriptive study on inpatients diagnosed with type 2 diabetes mellitus and kidney failure at the Department of Endocrinology. Data were collected during the hospital stay and at 3 months after discharge. We evaluate the the glycemic control using the rate of patients achieving target fasting plasma glucose (FPG) level and target HbA1c after 3 months of hospital discharge. Results: A total of 225 patients were included. Insulin monotherapy accounted for 95.02%. Oral monotherapy, metformin accounted for 3.29%. Combined metformin and gliclazide or metformin and acarbose accounted for 1.69%. After 3 months of treatment, the rate of achieving the target FPG level was 40.44%. The target HbA1c was 52.00%, in which the rate of achieving the target glycemic control is higher in patients with chronic kidney disease than in those with acute kidney injury. Conclusion: Insulin monotherapy is the main antidiabetic agent for 2 diabetes mellitus in patients with type kidney failure. After 3 months of treatment, the rates of achieving the target FPG and HbA1c were 40.44% and 52.00%, respectively. The rate of achieving the target glycemic control is higher in patients with chronic kidney disease than in those with acute kidney injury.
Article Details
Keywords
Diabetic nephropathy, insulin, fasting plasma glucose, HbA1c
References
2. Bộ Y tế (2017), Hướng dẫn chẩn đoán và điều trị đái tháo đường tuýp 2 ban hành kèm theo Quyết định số 3319/QĐ-BYT ngày 19 tháng 7 năm 2017 của Bộ trưởng Bộ Y tế.
3. Nguyễn Thị Hồng Giang (2018), Phân tích tình hình sử dụng thuốc và hiệu quả điều trị đái tháo đường tuýp 2 trên bệnh nhân có bệnh lý thận mạn tại Bệnh viện Đa khoa Xanh Pôn, Luận văn thạc sỹ dược học, trường Đại học Dược Hà Nội.
4. Nguyễn Thị Thanh Nga, Hoàng Trung Vinh, Nguyễn Thị Bích Đào, (2014), Biến đổi tình trạng kháng insulin, giai đoạn tổn thương thận trước và sau điều trị bệnh nhân đái tháo đường typ 2 có tổn thương thận, Nội tiết và Đái tháo đường, số 13, tr.47-51.
5. Lê Đình Tuân, Nguyễn Thị Hồ Lan (2017), Khảo sát đặc điểm biến chứng thận ở bệnh nhân đái tháo đường tuýp 2 điều trị ngoại trú tại Bệnh viện nội tiết Trung ương, Tạp chí Y dược học Quân sự. Số 6-2017, tr.55-62.
6. American Diabetes Association (2017), Standards of medical care in diabetes-2017: summary of revisions, Diabetes Care. 2017 Jan. 40 (Suppl 1) :S4-S5 PubMed PMID: 27979887.
7. Busch M., Lehmann T., et al. (2020), Antidiabetic Therapy and Rate of Severe Hypoglycaemia in Patients with Type 2 Diabetes and Chronic Kidney Disease of Different Stages – A Follow-up Analysis of Health Insurance Data from Germany, Thieme.
8. Kajiwara A., Kita A., Saruwatari J., et al. (2016), Sex differences in the renal function decline of patients with type 2 diabetes, J Diabetes Res. 2016:4626382.
9. Lee M.Y., Huang J.C., Chen S.C, et al. (2018), Association of HbA1C Variability and Renal Progression in Patients with Type 2 Diabetes with Chronic Kidney Disease Stages 3-4, Int. J. Mol. Sci. 19, pp.4116.
10. Lu J., Zhao W., Chen T., et al. (2020), Influence of guideline adherence and parameter control on the clinical outcomes in patients with diabetic nephropathy, BMJ Open Diab Res Care. 8(e001166).
11. Majumder A., Chaudhuri S.R., Sanyal D., (2019), A Retrospective Observational Study of Insulin Glargine in Type 2 Diabetic Patients with Advanced Chronic Kidney Disease, Cureus. 11(11), pp.e6191.
12. Nephrology, International Society of (2020), KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. 98(4S), pp.S1-S115.
13. Nephrology, International Society of (2012), KDIGO Clinical guideline for acute kidney injury, Kidney International, supplement 2, pp.13-138.
14. Rhee J.J., Han J., Montez-Rath M.E., et al. (2019), Antidiabetic medication use in patients with type 2 diabetes and chronic kidney disease, Journal of Diabetes and its Complications. 33(11).
15. Wu B., Bell K., et al. (2016), Understanding CKD among patients with T2DM: prevalence, temporal trends, and treatment patterns - NHANES 2007-2012, BMJ Open Diabetes Research and Care. 4, pp.e000154.